

## Full-length article

## Effects of aspirin on number, activity and inducible nitric oxide synthase of endothelial progenitor cells from peripheral blood<sup>1</sup>

Tu-gang CHEN, Jun-zhu CHEN<sup>2</sup>, Xu-dong XIE

Department of Cardiovascular Disease, First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou 310003, China

### Key words

aspirin; endothelial progenitor cells; cell adhesion; cell count; cell movement; cell division; physiologic neovascularization

<sup>1</sup> Project supported by Science and Technology Foundation of Zhejiang Province (No 021107613); Health Science Studying Foundation of Zhejiang Province (No 2003A043).

<sup>2</sup> Correspondence to Prof Jun-zhu CHEN.  
Phn 86-571-8723-0525.  
E-mail billctg@yahoo.com.cn

Received 2005-09-18

Accepted 2005-12-27

doi: 10.1111/j.1745-7254.2006.00298.x

### Abstract

**Aim:** To investigate whether aspirin has an influence on endothelial progenitor cells (EPC). **Methods:** Total mononuclear cells (MNC) were isolated from peripheral blood by Ficoll density gradient centrifugation, then cells were plated on fibronectin-coated culture dishes. After 7 d of culture, attached cells were stimulated with aspirin (to achieve final concentrations of 1, 2, 5, and 10 mmol/L) for 3, 6, 12, and 24 h. EPC were characterized as adherent cells that were double positive for 1,1-dioctadecyl-3,3,3-tetramethylindocarbocyanine low density lipoprotein (DiLDL) uptake and lectin binding by direct fluorescent staining. EPC proliferation and migration were assayed using a 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and a modified Boyden chamber assay, respectively. An EPC adhesion assay was performed by replating the EPC on fibronectin-coated dishes, and then adherent cells were counted. *In vitro* vasculogenesis activity was assayed by using an *in vitro* vasculogenesis kit. Inducible nitric oxide synthase (iNOS) was assayed by Western blotting. **Results:** Incubation of isolated human MNC with aspirin decreased the number of EPC. Aspirin also decreased the proliferative, migratory, adhesive, and *in vitro* vasculogenesis capacity of EPC, and also their iNOS levels in a concentration- and time-dependent manner. **Conclusion:** Aspirin decreases (1) the number of EPC; (2) the proliferative, migratory, adhesive and *in vitro* vasculogenesis capacities of EPC; and (3) iNOS levels in EPC.

### Introduction

Vascular endothelial progenitor cells (EPC) are the precursors of endothelial cells. Increasing evidence suggests that circulating progenitor cells contribute to postnatal neovascularization. These cells home to sites of ischemia, adopt an endothelial phenotype, and contribute to new blood vessel formation, but the identity of the circulating cells that contribute to neovascularization is not entirely clear. Bone-marrow-derived hematopoietic progenitor cells can give rise to endothelial progenitor cells and contribute to endothelial recovery and new capillary formation after ischemia.

Aspirin (acetylsalicylic acid) is widely used in the primary and secondary prevention of vascular disease<sup>[1]</sup>. The anti-inflammatory effect of aspirin it is believed to complement its platelet inhibitory effect, and be due to the inhibi-

tion of cyclooxygenase, resulting in decreased thromboxane A<sub>2</sub> production<sup>[2]</sup>. Although the major beneficial effect of aspirin is due to its inhibitory action on platelet aggregation, there is emerging evidence showing that other effects of aspirin on cells other than platelets may be equally important<sup>[3]</sup>. Therefore we investigated the effects of aspirin on the number and activity of endothelial progenitor cells from peripheral blood. Nitric oxide (NO) synthesized from *L*-arginine by inducible nitric oxide synthase (iNOS) is a very important signal pathway messenger in human endothelial cells<sup>[4,5]</sup>. We detected iNOS by western blotting and discuss the role of iNOS in these effects.

### Materials and methods

**Isolation and cultivation of EPC** Human EPC were ob-

tained from 6 healthy adults and cultured according to previously described techniques<sup>[6-8]</sup>. Written informed consent was obtained from all people involved in the study. Briefly, total mononuclear cells (MNC) were isolated from the blood of study subjects by Ficoll density gradient centrifugation. Cells were plated on culture dishes coated with human fibronectin (Chemicon) and maintained in Medium 199 (Sigma) supplemented with 20% fetal calf serum, penicillin (100 U/mL), and streptomycin (100 µg/mL). After 4 d of culture, nonadherent cells were removed by washing with phosphate-buffered saline (PBS), new media was added, and the culture was maintained through to d 7. Attached cells were stimulated with aspirin (Sigma; to achieve final concentrations of 1, 2, 5, and 10 mmol/L) for 3, 6, 12, and 24 h.

**Cellular staining** Fluorescent chemical detection of EPC was performed on attached MNC after 7 d in culture. Direct fluorescent staining was used to detect dual binding of fluorescein isothiocyanate (FITC)-labeled *Ulex europaeus* agglutinin (UEA-1; Sigma) and 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine (DiI)-labeled acetylated low-density lipoprotein (DiLDL; Molecular Probes). Cells were first incubated with DiLDL at 37 °C and later fixed with 2% paraformaldehyde for 10 min. After being washed, the cells were treated with UEA-1 (10 µg/mL) for 1 h. Samples were then viewed with an inverted fluorescent microscope (Leica) and a laser scanning confocal microscope (LSCM, Leica). Cells that were doubly fluorescent were identified as differentiating EPC<sup>[7-9]</sup>. Two or 3 independent investigators evaluated the number of EPC per well by counting 15 randomly selected high-power fields (×200) with an inverted fluorescent microscope.

**Migration assay** EPC migration was evaluated by using a modified Boyden chamber assay (Jiangsu Qilin Medical Equipment Factory, China). In brief, isolated EPC were detached using 0.25% trypsin, harvested by centrifugation, resuspended in 500 µL M199, and counted, then 2×10<sup>4</sup> EPC were placed in the upper chamber of a modified Boyden chamber. M199 and human recombinant VEGF (50 ng/mL) were placed in the lower compartment of the chamber. After 24 h incubation at 37 °C, the lower side of the filter was washed with PBS and fixed with 2% paraformaldehyde. For quantification, cells were stained with Giemsa solution. Cells migrating into the lower chamber were counted manually in 3 random microscopic fields (×200)<sup>[8,9]</sup>.

**Cell adhesion assay** EPC were washed with PBS and gently detached with 0.25% trypsin. After centrifugation and resuspension in M199 with 5% fetal bovine serum, identical cell numbers were replated onto fibronectin-coated culture dishes and incubated for 30 min at 37 °C. Adherent cells

were counted by independent blinded investigators<sup>[8,10]</sup>.

**EPC proliferation assay** The effect of aspirin on EPC proliferation was determined by 3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyl-2*H*-tetrazolium bromide (MTT) assay. After being cultured for 7 d, EPC were digested with 0.25% trypsin and then cultured in serum-free medium in 96-well culture plates (200 µL per well). EPC were supplemented with 10 µL MTT (5 g/L) and incubated for another 6 h. Then the supernatant was discarded by aspiration and the EPC preparation was shaken with 200 µL Me<sub>2</sub>SO for 10 min, before the optical density (OD) value was measured at 490 nm<sup>[8]</sup>.

**In vitro vasculogenesis assay** The *in vitro* vasculogenesis assay was performed with an *in vitro* Angiogenesis Assay Kit (Chemicon) according to the manufacturer's instructions. Briefly, ECMatrix solution was thawed on ice overnight, then mixed with 10× ECMatrix diluent and placed in a 96-well tissue culture plate at 37 °C for 1 h to allow the matrix solution to solidify. EPC were harvested as described earlier and replated (1×10<sup>4</sup> cells per well) on top of the solidified matrix solution. Cells were incubated at 37 °C for 24 h. Tubule formation was inspected under an inverted light microscope at 200× magnification. Tubule formation was defined as development of a structure with a length at least 4 times its width<sup>[8,11,12]</sup>. Five independent fields were assessed for each well, and the average number of tubules per 200× field was determined.

**Western blot analysis for iNOS** The cell monolayers were washed 3 times with PBS and lysed with RIPA buffer containing phenylmethylsulfonyl fluoride and aprotinin as protease inhibitors. The cell lysates (30 µg total protein) were denatured and subjected to 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred to nitrocellulose membranes by electroblotting. The membranes were soaked in a blocking solution containing PBS with 5% non-fat dried milk and 0.05% Tween 20 for 1 h at room temperature. The membranes were incubated with iNOS monoclonal antibodies (Santa Cruz Biotechnology) for 2 h and then with peroxidase-conjugated secondary antibodies for 2 h at room temperature. The bands corresponding to iNOS were detected using a chemiluminescence reagent (Amersham).

**Statistical analysis** Data are expressed as mean±SD. We used one-way ANOVA and the independent-samples *t*-test to analyze the differences in variables. The differences were considered significant if the *P*<0.05. All statistical analyses were performed with SPSS 11.5.

## Results

**Characteristics of human EPC** Total MNC that were


isolated and cultured for 7 d were spindle-shaped, with an endothelial cell-like morphology. EPC were characterized as adherent cells that were double-positive for DiLDL-uptake and lectin binding under a laser scanning confocal microscope (Figure 1). We and other investigators have previously demonstrated that endothelial progenitor cells isolated in this fashion also exhibit many other endothelial characteristics, including expression of CD31, von Willebrand factor, and vascular endothelial growth factor receptor 2<sup>[7-9,11]</sup>.

**Effect of aspirin on number of EPC** Incubation of isolated human MNC with aspirin decreased the number of EPC in a concentration- and time-dependent manner (Figure 2).


**Effects of aspirin on the proliferative capacity of isolated EPC** Incubation of isolated human MNC with aspirin decreased EPC proliferative capacity in a concentration- and time-dependent manner (Figure 3).

**Effects of aspirin on the migratory capacity of isolated EPC** Incubation of isolated human MNC with aspirin decreased EPC migratory capacity in a concentration- and time-dependent manner (Figure 4).


**Effect of aspirin on the adhesive capacity of isolated EPC** Incubation of isolated human MNC with aspirin decreased EPC adhesive capacity in a concentration- and time-dependent manner (Figure 5).




**Figure 1.** Mononuclear cells were cultured for 7 d, and adherent cells that bound lectin (green, excitation wavelength 477 nm) or took up DiLDL (red, excitation wavelength 543 nm) were assessed under a laser scanning confocal microscope. Double positive cells appearing yellow in the overlay were identified as differentiating EPC ( $\times 400$ ). The group treated with 5 mmol/L aspirin (B1, B2, B3) had a significantly smaller number of EPC compared with the control group (A1, A2, A3).




**Figure 2.** Effects of different concentrations of aspirin on EPC number (A) and effect of 5 mmol/L aspirin on EPC number over time (B). Aspirin decreased the number of EPC in a concentration- and time-dependent manner.  $n=6$ . Mean $\pm$ SD. <sup>c</sup> $P<0.01$  vs control.



**Figure 3.** Effects of different concentrations of aspirin on EPC proliferation (A) and effect of 5 mmol/L aspirin on EPC proliferation over time (B). Aspirin decreased EPC proliferative capacity in a concentration- and time-dependent manner.  $n=6$ . Mean±SD. <sup>b</sup> $P<0.05$ , <sup>c</sup> $P<0.01$  vs control.



**Figure 4.** Effects of different concentrations of aspirin on EPC migration (A) and effect of 5 mmol/L aspirin on EPC migration over time (B). Aspirin decreased EPC migratory capacity in a concentration- and time-dependent manner.  $n=6$ . Mean±SD. <sup>b</sup> $P<0.05$  vs control, <sup>c</sup> $P<0.01$  vs control.



**Figure 5.** Effects of different concentrations of aspirin on EPC adhesion (A) and effect of 5 mmol/L aspirin on EPC adhesion over time (B). Aspirin decreased EPC adhesive capacity in a concentration- and time-dependent manner.  $n=6$ . Mean±SD. <sup>b</sup> $P<0.05$  vs control, <sup>c</sup> $P<0.01$  vs control.


**Effects of aspirin on EPC *in vitro* vasculogenesis** Incubation of isolated human MNC with aspirin decreased the *in vitro* vasculogenesis capacity of EPC cells in a concentration-dependent manner (Figure 6).

**Effects of aspirin on EPC iNOS** Western blot analysis showed that the expression of iNOS was significantly decreased by aspirin in a concentration-dependent manner


(Figure 7), strongly suggesting that the inhibitory effect of aspirin is mediated through decreasing NO.

## Discussion

There is strong evidence that EPC plays a significant role in neovascularization and re-endothelialization, particu-



**Figure 6.** Effects of different concentrations of aspirin on EPC *in vitro* vasculogenesis capacity. Aspirin decreased the EPC *in vitro* vasculogenesis capacity in a concentration-dependent manner. <sup>c</sup>*P*<0.01 vs control.



**Figure 7.** Western blot of the effects of different concentrations of aspirin on the iNOS production of EPC. iNOS production by EPC was significantly decreased by aspirin in a concentration-dependent manner. <sup>c</sup>*P*<0.01 vs control. Lane 1: control; lane 2: 1 mmol/L aspirin; lane 3: 2 mmol/L aspirin; line 4: 5 mmol/L aspirin; lane 5: 10 mmol/L aspirin.

larly under ischemic conditions. Recently, it has been noted in animal and human subjects that EPC contribute up to 25% of endothelial cells in newly formed vessels<sup>[13,14]</sup>. Thus, increasing the number of circulating EPC by transplantation of hematopoietic stem cells or by injection of *in vitro* differentiated EPC has been shown to improve neovascularization of ischemic hindlimbs<sup>[15]</sup>, accelerate blood flow in diabetic mice<sup>[16]</sup>, and improve cardiac function<sup>[17]</sup>. Moreover, Vasa *et al* have recently reported that patients with coronary heart disease (CHD) have reduced levels and functional impairment of EPC, which correlate with risk factors for CHD<sup>[9]</sup>. In addition, we have previously observed that hyperhomocysteine, a major risk factor for cardiovascular diseases,

induces a reduction in EPC levels with decreased functional activity *in vitro*<sup>[8]</sup>. Therefore, stimulation of mobilization and/or differentiation of EPC may provide a useful novel therapeutic strategy to improve postnatal neovascularization and re-endothelialization in patients with CHD.

Aspirin is widely used in the primary and secondary prevention of vascular disease. The anti-inflammatory effect of salicylates is believed to complement their platelet inhibitory effect and is thought to be due to the inhibition of cyclooxygenase, resulting in decreased thromboxane A<sub>2</sub> production. Aspirin inhibits cyclooxygenase by acetylating the serine residue in the active site of the enzyme<sup>[18,19]</sup>. Bernhardt *et al*<sup>[20]</sup> have reported that high concentrations of aspirin can inhibit smooth muscle cell proliferation. Marra *et al*<sup>[21]</sup> have shown that aspirin inhibits the proliferation of smooth muscle cells through inhibition of cyclin-dependent kinases, which hyperphosphorylate the retinoblastoma protein. Oberle *et al*<sup>[22]</sup> have discovered that aspirin increases the resistance of endothelial cells to assault by free radicals through ferritin synthesis. An antiarrhythmic effect of aspirin has been found in platelet-depleted dogs subjected to coronary occlusion<sup>[23]</sup>. Kharbanda *et al*<sup>[24]</sup> have reported a protective effect of aspirin against endothelial dysfunction. Husain *et al*<sup>[25]</sup> have reported that improvement of endothelial dysfunction with aspirin may improve vasodilation, reduce thrombosis, and inhibit the progression of athero-sclerosis. Ranganathan *et al*<sup>[26]</sup> have reported that aspirin inhibits the synthesis of protein and DNA by upregulation of p53 expression in endothelial cells. p53 is an inhibitor of cyclin-dependent kinases (Cdk)<sup>[27]</sup>. Activation of Cdk is important in the hyperphosphorylation of retinoblastoma protein, which activates the transcription of several genes required for the progression of the cell cycle<sup>[28]</sup>. The present study shows that aspirin (1) decreases the number of EPC; (2) decreases the proliferative, migratory, adhesive, and *in vitro* vasculogenesis capacity of EPC; and (3) decreases EPC production of iNOS in a concentration- and time-dependent manner. Katsuyama *et al*<sup>[29]</sup> showed that aspirin dose-dependently inhibited cytokine-stimulated NO production and iNOS protein expression. NO can enhance EPC proliferation and function through activating the PI3K/Akt signal pathway<sup>[30,31]</sup>.

Circulating EPC are constantly exposed to inflammatory factors, such as cytokines and oxidized lipoproteins. Atherosclerosis in general is indicative of a low grade inflammatory process, and atherosclerotic plaques that are prone to rupture and result in acute coronary syndromes reveal an intense inflammatory state<sup>[32,33]</sup>. Therefore, the effects of aspirin on EPC in the inflammatory condition must be

studied further. Aspirin is a cornerstone of therapy in acute coronary syndromes<sup>[1,3]</sup>, and has been shown to reduce atherosclerosis-related events in a multitude of clinical studies<sup>[34]</sup>. Although most of the benefits of aspirin have been ascribed to its anti-platelet aggregatory properties, non-platelet-mediated effects are also thought to contribute to its salutary effect.

## References

- 1 Awtry EH, Loscalzo J. Aspirin. *Circulation* 2000; 101: 1206–15.
- 2 Weissmann G. Aspirin. *Sci Am* 1991; 264: 84–90.
- 3 Mehta JL. Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. *Clin Cardiol* 1998; 21: 879–84.
- 4 Guo X, Chen LW, Liu WL, Guo ZG. High glucose inhibits expression of inducible and constitutive nitric oxide synthase in bovine aortic endothelial cells. *Acta Pharmacol Sin* 2000; 21: 325–8.
- 5 Natarajan R, Jones DG, Fisher BJ, Wallace TJ, Ghosh S, Fowler Iii AA. Hypoxia inducible factor-1: regulation by nitric oxide in posthypoxic microvascular endothelium. *Biochem Cell Biol* 2005; 83: 597–607.
- 6 Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, *et al*. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med* 2003; 348: 593–600.
- 7 Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, *et al*. Transplantation of *ex vivo* expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci USA* 2000; 97: 3422–7.
- 8 Chen JZ, Zhu JH, Wang XX, Zhu JH, Xie XD, Sun J, *et al*. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. *J Mol Cell Cardiol* 2004; 36: 233–9.
- 9 Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, *et al*. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 2001; 89: E1–E7.
- 10 Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, *et al*. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. *Circulation* 2002; 105: 3017–24.
- 11 Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, *et al*. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. *Circulation* 2002; 106: 2781–6.
- 12 Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. *J Clin Invest* 2002; 109: 337–46.
- 13 Murayama T, Tepper OM, Silver M, Ma H, Losordo DW, Isner JM, *et al*. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization. *Exp Hematol* 2002; 30: 967–72.
- 14 Suzuki T, Nishida M, Futami S, Fukino K, Amaki T, Aizawa K, *et al*. Neendothelialization after peripheral blood stem cell transplantation in humans. A case report of a Tokaimura nuclear accident victim. *Cardiovasc Res* 2003; 58: 487–92.
- 15 Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H, *et al*. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. *J Clin Invest* 2000; 105: 1527–36.
- 16 Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. *J Clin Invest* 2000; 106: 571–8.
- 17 Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkoff D, Wang J, *et al*. Neovascularization of ischemic myocardium by human bone-marrow derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 2001; 7: 430–6.
- 18 Roth GJ, Majerus PW. The mechanism of the effect of aspirin in human platelets. *J Clin Invest* 1975; 56: 624–32.
- 19 Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. *J Biol Chem* 1994; 269: 13207–15.
- 20 Bernhardt J, Rogalla K, Luscher TF, Buhler FR, Resink TJ. Acetylsalicylic acid, at high concentrations, inhibits vascular smooth muscle cell proliferation. *J Cardiovasc Pharmacol* 1993; 21: 973–6.
- 21 Marra DE, Simoncini T, Liao JK. Inhibition of vascular smooth muscle proliferation by sodium salicylate mediated by upregulation of p21<sup>Waf1</sup> and p27<sup>Kip1</sup>. *Circulation* 2000; 102: 2124–30.
- 22 Oberle S, Polte T, Abate A, Podhaisky HP, Schroder H. Aspirin increases ferritin synthesis in endothelial cells. *Circ Res* 1998; 82: 1016–20.
- 23 Moschos CB, Lahiri K, Peter A, Jesrani MU, Regan TJ. Effect of aspirin upon experimental coronary and non-coronary thrombosis and arrhythmia. *Am Heart J* 1972; 84: 525–30.
- 24 Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, MacAllister RJ, *et al*. Prevention of inflammation induced endothelial dysfunction. *Circulation* 2002; 105: 2600–4.
- 25 Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. *Circulation* 1998; 97: 716–20.
- 26 Ranganathan S, Joseph J, Mehta JL. Aspirin inhibits human coronary artery endothelial cell proliferation by upregulation of p53. *Biochem Biophys Res Commun* 2003; 301: 143–6.
- 27 Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell* 1997; 88: 323–31.
- 28 La Thangue NB. E2F and the molecular mechanisms of early cell-cycle control. *Biochem Soc Trans* 1996; 24: 54–9.
- 29 Katsuyama K, Shichiri M, Kato H, Imai T, Marumo F, Hirata Y. Differential inhibitory actions by glucocorticoid and aspirin on cytokine-induced nitric oxide production in vascular smooth muscle cells. *Endocrinology* 1999; 140: 2183–90.
- 30 Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, *et al*. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. *J Clin Invest* 2001; 108: 391–7.
- 31 Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, *et al*. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. *Circula-*

- tion 2001; 103: 2885–90.
- 32 Mehta JL, Li DY. Inflammation in ischemic heart disease; response to tissue injury or a pathogenetic villain. *Cardiovasc Res* 1999; 43: 291–9.
- 33 Kinlay S, Selwyn AP, Libby P, Ganz P. Inflammation, the endothelium, and the acute coronary syndromes. *J Cardiovasc Pharmacol* 1998; 32 Suppl 3: S62–S66.
- 34 Antiplatelet Trialists' Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy: collaborative meta-analysis of 266 trials involving 200,000 patients at high risk of occlusive vascular events. *Br Med J* 2002; 324: 71–86.
- 

International Symposium  
on the Genomic Hypertension Research and Therapy  
(GHRT-2006, Taipei)

November 2–5, 2006, Taipei International Convention Center, Taipei, China

Info: GHRT-2006 Secretariat  
c/o Department of Pharmacology  
Kinki University School of Medicine  
377-2 Ohno-Higashi, Osakasayama-shi  
Osaka 589-8511, Japan  
Fax 81-723-67-182  
E-mail [higashino@med.kindai.ac.jp](mailto:higashino@med.kindai.ac.jp)